Used in the treatment of systemic lupus erythematosus (SLE), particularly targeting patients with active disease who may not respond adequately to standard therapies. It is an antisense oligonucleotide designed to inhibit the production of B-cell activating factor (BAFF), a protein involved in B-cell survival and activation. By reducing BAFF levels, the compound helps decrease the autoimmune response associated with lupus, potentially reducing disease activity and flare-ups. It is administered via subcutaneous injection and has been investigated in clinical trials to evaluate its efficacy and safety in improving outcomes for lupus patients, including those with lupus nephritis.